Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| ADC Therapeutics SA | ADCT | NYSE | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.0% | 1.11 | 18:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.11 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 0.359908 - 5.75 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 1.11 | USD |
ADC Therapeutics SA Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 89.51M | 80.64M | - | 209.91M | -155.8M | -1.93 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
ADC Therapeutics News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ADCT Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.725 | 1.1737 | 0.6883 | 0.981601 | 704,186 | 0.385 | 53.1% |
| 1 Month | 0.8035 | 1.1737 | 0.359908 | 0.7452552 | 447,610 | 0.3065 | 38.15% |
| 3 Months | 1.00 | 1.1737 | 0.359908 | 0.7799552 | 338,092 | 0.11 | 11.0% |
| 6 Months | 2.49 | 2.64 | 0.359908 | 1.33 | 399,220 | -1.38 | -55.42% |
| 1 Year | 3.63 | 5.75 | 0.359908 | 2.44 | 552,415 | -2.52 | -69.42% |
| 3 Years | 33.33 | 37.82 | 0.359908 | 9.90 | 360,707 | -32.22 | -96.67% |
| 5 Years | 30.00 | 56.5899 | 0.359908 | 12.75 | 338,668 | -28.89 | -96.3% |
ADC Therapeutics Description
| ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212. |
